De har deres egen teknologi platform, som lige har opnået patent i USA. Det giver dem mulighed for at tjene penge som "underleverandør" af targets for nye antistoffer til de store medicinalfirmaer. Det lægger en hånd under cashburn og emmissioner.

Kursmæssigt har Bioinvent levet en omtumlet tilværelse. De havde partneraftaler med store Genetech (blåstempling), men deres førende stoffer fejlede i de kliniske forsøg (ja, det kan ske !) og de er blev slået tilbage til start. Kursen er faldet fra omkring 30 SEK til nu 3-4 SEK.

Men de har skåret virksomheden og omkostningerne til og vil nu leve af tidlige partnerskabsaftaler med de store firmaer (har lige indgået ny aftale med Bayer), og de har pt. 3 stoffer enten i start fase 2 eller tæt på klinisk udvikling. Som jeg har forstået det, så er tanken at lave partner aftale på det mest fremskrende stof (BI-505 inden alt for længe)

De har også 8 stoffer i tidlig udvikling med 5 partnere og som jeg læser deres seneste kvartalsrapport har de yderligere over 10 forskningsprojekter på vej.

Redirecting to https://www.bioinvent.se/en/404

(bioinvent.se)

Det interessante er, at targets for disse stoffer ligner eller er komplementære til nogle af Genmabs (derfor jeg kaldte den baby-Genmab). Risikoen er jo mange gange højere end Genmab, men markedsværdien er også kun 3-4 procent af Genmabs (nogle hundrede mio kr.), så potentialet er også stort. De er vel mindst 5 år længere tilbage end Genmab.

Jeg tænker, hvis de på BI-505 kan lave en aftale der bare ligner lidt den Genmab fik med Daratumumab, så kan der for alvor blive fest og farver her. BI-1206 ser ud til at kunne bruges i kombination med Arzzera eller Rituxan, så det er også spændende.

Jeg har selv taget 10.000 stk.

Redirecting to https://www.bioinvent.com/sv

(bioinvent.se)

Product description
BI-505 is a fully human antibody derived from BioInvent's proprietary n-CoDeR library. The antibody binds to the adhesion protein ICAM-1 (CD54), which is overexpressed in several tumours but not widely expressed in normal tissue. BI-505 is being developed to treat multiple myelomas that express ICAM-1.
Product rationale
BI-505 was identified in a screen to find antibodies that can cause cell death (apoptosis). Antibodies with this property could be used to kill cancer cells to which they bind.
Prior to BioInvent's screen and preclinical studies, the ability of anti-ICAM-1 to lead to apoptosis had not been recognised. Owing to its novel mode of action, BI-505 could be given to patients that do not respond to current treatments.
Clinical status
A dose-escalation phase I study in patients with relapsed or refractory multiple myeloma is on-going. The study explores safety, pharmacokinetics and pharmacodynamics, such as relevant biomarkers for tumour response, with the aim of defining the optimal dose of the antibody for future clinical development. Patients are treated with intravenous doses of BI-505 every second week for a 28-day period with the possibility of extending the treatment until the condition deteriorates.
BI-505 has been granted orphan drug designation for the treatment of multiple myeloma by both the FDA and the European Agency for the Evaluation of Medicines (EMEA).
Development and commercialisation strategy
We are currently developing BI-505 in house at BioInvent.

BI-1206
Background
BI-1206 is a so-called antagonistic (blocking) antibody aimed at the immunosuppressive target protein Fc gamma receptor IIB, CD32b. CD32b is overexpressed on tumour cells in patients with lymphoma, especially in patients who respond poorly to currently available drugs. Data show that CD32b is directly involved in the development of tumour cell resistance to the current state-of-the-art treatment -Rituximab (Mabthera, Rituxan, Roche), an antibody directed against target protein CD20. Combined treatment with BI-1206 and rituximab has shown significantly enhanced antitumour effects in clinically relevant animal models of patients' tumour cells, compared with monotherapy with rituximab. Combination therapy therefore has the potential to significantly improve treatment of patients with nonHodgkin's lymphoma. BI-1206 has also shown a strong ability to kill lymphoma cells on its own in preclinical models using tumour cells taken directly from patients. Moreover, other groups have shown that animals lacking CD32b (CD32b knockout mice) respond better to antibody treatment and are better able to kill tumour cells in a lung cancer model compared with animals that have the CD32b protein. These results show that BI-1206 also has the potential to be used as monotherapy and that by shutting off the immunosuppressive effect of CD32b and creating a more immunostimulatory environment, it can enhance the therapeutic effect of several previously approved antibody-based drugs other than rituximab. BI-1206 will initially be developed for non-Hodgkin's lymphoma lymphoma (including chronic lymphocytic leukaemia), the most common type of hematologic cancer. Preclinical studies are also planned for assessment of the potential of this antibody to be effective for other types of hematologic cancer, for solid tumours and in combination with antibodies other than rituximab. The product will be developed in cooperation with a leading research group in Southampton, UK. BioInvent believes that market for treatment with BI-1206 combined with other antibodies is significant. In 2012, Rituxan alone had sales of USD 7.1 billion, the majority for hematologic cancer, which makes it the second most sold antibody-based drug worldwide. In various studies, up to half of all cancer patients who responded to an initial course of Rituxan proved to be resistant to the drug on recurrence of the disease.
Project status
Development of the production process for BI-1206 has begun. The next stage of development after up-scaling and production involves toxicological studies, which are expected to begin in early 2014.

ADC-1013
Background
ACD-1013 is a so-called agonistic (activating) immunostimulatory antibody developed for local administration into tumour tissue (intratumoural administration). The antibody is directed against the CD40 antigen, which is expressed on several types of immune system cells and stimulation of this protein activates the body's own defence mechanisms against cancer. CD40 is also expressed on several types of tumours, including lymphoma. ADC-1013 and a mouse-specific surrogate antibody have been studied in several different tumour models and consistently shown very promising effects. For example, it has been shown that local administration causes systemic immune activation, resulting in eradication of metastases. In addition, long-lasting immunity against the cancer is also created, thereby protecting against new metastases even after discontinuation of treatment. It has also been shown that the effect can be achieved at lower doses than when administering the antibody systemically, and that the risk of side effects is lower at the same doses. The product is FIND- optimised from an origin antibody selected from BioInvent's n-CoDeR antibody library. Development of ADC-1013 to date has been carried out by Alligator Bioscience, a Swedish Lund-based biotech company.
Project status
BioInvent obtained the right to co-develop the product candidate ADC-1013 with Alligator Bioscience through an option agreement. The parties will share future costs and revenues from the project equally. Development of the production process for ADC-1013 has begun. The next stage of development after up-scaling and production involves toxicological studies, which are expected to be carried out in 2013. Clinical investigation of ADC-1013 in cancer patients is expected to begin in the first half of 2014. Clinical investigation of ADC-1013 in cancer patients is expected to begin in the first half of next year.